These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1022953)

  • 61. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of dapsone on blood lactic and pyruvic acids in leprosy.
    Sinha SN; Gupta SC; Bajaj AK; Srivastava NP; Mehrotra TN
    Int J Lepr Other Mycobact Dis; 1982 Dec; 50(4):468-70. PubMed ID: 6892022
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous leprosy.
    Kar HK; Bhatia VN; Kumar CH; Sirumban P; Roy RG
    Indian J Lepr; 1986; 58(4):592-600. PubMed ID: 3572102
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Current guidelines for leprosy treatment].
    Flageul B
    Bull Soc Pathol Exot; 2003 Jan; 96(5):357-61. PubMed ID: 15015839
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Levamisole in cases of E.N.L.
    Arora SK; Singh G; Sen PC
    Indian J Lepr; 1985; 57(1):17-21. PubMed ID: 3897404
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical evaluation studies in lepromatous leprosy. Sixth series: effect (on lepra reaction) of supplementing DDS with dexamethasone, methandrostenolone, or mefenamic acid.
    Doull JA; Tolentino JG; Guinto RS; Rodriguez JN; Leano LM; Fernandez JV; Rivera JN; Fajardo TT
    Int J Lepr Other Mycobact Dis; 1967; 35(2):128-39. PubMed ID: 5338957
    [No Abstract]   [Full Text] [Related]  

  • 67. Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):161-72. PubMed ID: 1522358
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy.
    Rea TH
    Int J Lepr Other Mycobact Dis; 2001 Dec; 69(4):318-27. PubMed ID: 12035293
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Clinical and bacteriological assessment 8 years after triple-drug therapy for multibacillary leprosy in Senegal].
    Dousset-Faure I; Millan J; Decazes JM; Languillon J
    Acta Leprol; 1986; 4(4):465-72. PubMed ID: 3296618
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A double-blind controlled clinical trial to assess the role of anti-histamines in the treatment of multi-bacillary leprosy.
    Thomas A; Nagarajan M; Chandrasekaran V; Hari L; Somasundaram PR; Prabhakar R; Kumar A; Bhatia VN; Roy RG
    Indian J Lepr; 1988 Oct; 60(4):499-505. PubMed ID: 3075630
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Transformation from lepromatous to borderline leprosy under clofazimine therapy.
    Mahapatra SB; Ramu G
    Lepr India; 1976 Apr; 48(2):172-6. PubMed ID: 1022964
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Simultaneous upgrading reaction and erythema nodosum leprosum in a patient with lepromatous leprosy.
    Job CK; Jacobson RR; Hastings RC
    Int J Lepr Other Mycobact Dis; 1988 Sep; 56(3):437-42. PubMed ID: 3418207
    [TBL] [Abstract][Full Text] [Related]  

  • 73. L.D.H. isoenzymes sub-unit ratio in leprosy and the effect of clofazimine treatment on L.D.H. isoenzymes sub-unit.
    Bulakh PM; Ranade SM; Kowale CN; Chandorkar AG; Burte NP
    Indian J Lepr; 1985; 57(1):115-23. PubMed ID: 3839809
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Type II (ENL) reaction in histoid leprosy in a child.
    Sehgal VN; Chaudary AK; Mahajan DM; Bedi BS
    Lepr Rev; 1991 Dec; 62(4):431-2. PubMed ID: 1784159
    [No Abstract]   [Full Text] [Related]  

  • 75. [New drugs in the treatment of leprosy].
    De Las Aguas JT
    Med Cutan Ibero Lat Am; 1976; 4(5):365-70. PubMed ID: 1035391
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The use of an ultralong-acting sulphonamide (Fanasil) as a prophylactic agent.
    Stein H; Cohen H; Katze H; Goldberg J
    S Afr Med J; 1972 Sep; 46(38):1370. PubMed ID: 4638225
    [No Abstract]   [Full Text] [Related]  

  • 77. [Letter: Lepromatous leprosy. Unknown contra-indication of antivariolar vaccination].
    Bastin R; Charmot G; Bonizzoni D; Girouin D; Kernbaum S; Bricaire F; Dif A
    Nouv Presse Med; 1976 Apr; 5(17):1143-4. PubMed ID: 934830
    [No Abstract]   [Full Text] [Related]  

  • 78. Passive transfer of immunity into leprosy patients by transfusion of lymphocytes and by transfusion of Lawrence's transfer factor.
    Saha K; Mittal MM; Maheshwari HB
    J Clin Microbiol; 1975 Mar; 1(3):279-88. PubMed ID: 1176605
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ultralong-acting sulphonamide (Fanasil).
    Taylor GM
    S Afr Med J; 1972 Oct; 46(43):1602. PubMed ID: 4642084
    [No Abstract]   [Full Text] [Related]  

  • 80. The treatment of leprosy and its acute complications.
    Jopling WH
    Trop Doct; 1973 Jan; 3(1):8-11. PubMed ID: 4120944
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.